These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17584140)

  • 21. Cholecystokinin antagonists: pharmacological and therapeutic potential.
    Herranz R
    Med Res Rev; 2003 Sep; 23(5):559-605. PubMed ID: 12789687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists.
    Bock MG; DiPardo RM; Newton RC; Bergman JM; Veber DF; Freedman SB; Smith AJ; Chapman KL; Patel S; Kemp JA
    Bioorg Med Chem; 1994 Sep; 2(9):987-98. PubMed ID: 7712133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target.
    Miller LJ; Desai AJ
    Trends Endocrinol Metab; 2016 Sep; 27(9):609-619. PubMed ID: 27156041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists).
    de Tullio P; Delarge J; Pirotte B
    Curr Med Chem; 1999 Jun; 6(6):433-55. PubMed ID: 10213792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1)receptor antagonists: structure-activity relationship studies on the substituent at N2-position.
    Bartolomé-Nebreda JM; Patiño-Molina R; Martín-Martínez M; Gómez-Monterrey I; García-López MT; González-Muñiz R; Cenarruzabeitia E; Latorre M; Del Río J; Herranz R
    J Med Chem; 2001 Jun; 44(13):2219-28. PubMed ID: 11405658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of the chemical structure of peptides as the starting point to design nonpeptide agonists and antagonists at peptide receptors: examples with cholecystokinin and tachykinins.
    Horwell DC
    Bioorg Med Chem; 1996 Oct; 4(10):1573-6. PubMed ID: 8931926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones.
    Beinborn M; Chen C; DeMeo L; McBride EW; Kopin AS
    Yale J Biol Med; 1998; 71(3-4):337-46. PubMed ID: 10461364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.
    Low CM; Black JW; Broughton HB; Buck IM; Davies JM; Dunstone DJ; Hull RA; Kalindjian SB; McDonald IM; Pether MJ; Shankley NP; Steel KI
    J Med Chem; 2000 Sep; 43(19):3505-17. PubMed ID: 11000005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conformationally constrained CCK8 analogues obtained from a rationally designed peptide library as ligands for cholecystokinin type B receptor.
    De Luca S; Saviano M; Della Moglie R; Digilio G; Bracco C; Aloj L; Tarallo L; Pedone C; Morelli G
    ChemMedChem; 2006 Sep; 1(9):997-1006. PubMed ID: 16915602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.
    Desai AJ; Lam PC; Orry A; Abagyan R; Christopoulos A; Sexton PM; Miller LJ
    J Med Chem; 2015 Dec; 58(24):9562-77. PubMed ID: 26654202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CCK-B/Gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides.
    Bläker M; Ren Y; Seshadri L; McBride EW; Beinborn M; Kopin AS
    Mol Pharmacol; 2000 Aug; 58(2):399-406. PubMed ID: 10908308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a CCK1R-membrane nanoparticle as a fish-out tool for bioactive peptides.
    Staljanssens D; Rico CA; Park M; Van Camp J; Yu N; Huber T; Sakmar TP; Smagghe G
    Peptides; 2015 Jun; 68():219-27. PubMed ID: 25451329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anthranilic acid based CCK1 receptor antagonists: blocking the receptor with the same 'words' of the endogenous ligand.
    Lassiani L; Pavan MV; Berti F; Kokotos G; Markidis T; Mennuni L; Makovec F; Varnavas A
    Bioorg Med Chem; 2009 Mar; 17(6):2336-50. PubMed ID: 19261479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179.
    Silvente Poirot S; Hadjiivanova C; Escrieut C; Dufresne M; Martinez J; Vaysse N; Fourmy D
    Eur J Biochem; 1993 Mar; 212(2):529-38. PubMed ID: 8444190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The CCK(-like) receptor in the animal kingdom: functions, evolution and structures.
    Staljanssens D; Azari EK; Christiaens O; Beaufays J; Lins L; Van Camp J; Smagghe G
    Peptides; 2011 Mar; 32(3):607-19. PubMed ID: 21167241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.
    Evans BE; Rittle KE; Bock MG; DiPardo RM; Freidinger RM; Whitter WL; Lundell GF; Veber DF; Anderson PS; Chang RS
    J Med Chem; 1988 Dec; 31(12):2235-46. PubMed ID: 2848124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for positive allosteric modulators of cholecystokinin type 1 receptor potentially useful for management of obesity.
    Dengler DG; Sun Q; Harikumar KG; Miller LJ; Sergienko EA
    SLAS Discov; 2022 Oct; 27(7):384-394. PubMed ID: 35850480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 'Targeted' molecular diversity: design and development of non-peptide antagonists for cholecystokinin and tachykinin receptors.
    Horwell D; Pritchard M; Raphy J; Ratcliffe G
    Immunopharmacology; 1996 Jun; 33(1-3):68-72. PubMed ID: 8856117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Highly constrained dipeptoid analogues containing a type II' beta-turn mimic as novel and selective CCK-A receptor ligands.
    de la Figuera N; Martín-Martínez M; Herranz R; García-López MT; Latorre M; Cenarruzabeitia E; del Río J; González-Muñiz R
    Bioorg Med Chem Lett; 1999 Jan; 9(1):43-8. PubMed ID: 9990454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Full and partial agonist activity of C-terminal cholecystokinin peptides at the cloned human CCK-A receptor expressed in Chinese hamster ovary cells.
    Dunlop J; Zhang Y; Evans N
    Peptides; 1997; 18(6):865-8. PubMed ID: 9285936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.